Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors
Journal of Neural Transmission · 2025-11 · 132 (11) · 1751-1760
DOI: 10.1007/s00702-025-03042-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neural Transmission, online erschienen am 15.10.2025. Verfasst von Brittney Yegla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Supernus Pharmaceuticals Inc, 9715 Key West Ave, Rockville, MD, 20850, USA. byegla@supernus.com. Hauptthemen laut MEDLINE: Apomorphine, Cyclic AMP, Dopamine Agonists, Signal Transduction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Supernus Pharmaceuticals.
Abstract (Originalsprache)
Apomorphine is the only dopamine agonist used to treat Parkinson disease with similar efficacy to levodopa. Its original characterization as a dopamine agonist was based on its receptor binding profile and capacity to recruit G proteins; however, current knowledge of G protein-coupled receptors highlights the importance of β-arrestin signaling to dopamine receptor functionality and expression. This study systematically compared the activity of apomorphine and dopamine across the range of dopamine receptor subtypes using biosensor assays that assessed its functional effects on both the cAMP and β-arrestin signaling pathways. Apomorphine facilitated cAMP signaling at both D1 and D2 family receptors with similar efficacy to dopamine but greater potency except at D3 receptors, where it exhibited similar potency. Apomorphine also recruited β-arrestin at all dopamine receptors similar to dopamine but with lower maximal effects at D1, D4, and D5 receptors. The potent efficacy of apomorphine on cAMP signaling at all dopamine receptor subtypes may explain its similar efficacy to levodopa. The clinical impact of the β-arrestin effects requires further study but is likely to influence its pharmacodynamic effects, including differences in adverse event profile compared to levodopa and D2-preferring agonists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Supernus Pharmaceuticals Inc, 9715 Key West Ave, Rockville, MD, 20850, USA. byegla@supernus.com.
- Supernus Pharmaceuticals Inc, 9715 Key West Ave, Rockville, MD, 20850, USA.
- Faculty of Life Sciences and Medicine, Institute of Pharmaceutical Sciences, King's College London, London, UK.
ORCID-Profile: Jonathan Rubin, Mindy Grall, Andrea Formella, Peter Jenner
Förderung
- Supernus Pharmaceuticals
Zitieren
APA
Yegla, B., Rubin, J., Grall, M., Formella, A., & Jenner, P. (2025). Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors. Journal of Neural Transmission, 132(11), 1751-1760. https://doi.org/10.1007/s00702-025-03042-7
Vancouver
Yegla B, Rubin J, Grall M, Formella A, Jenner P. Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors. Journal of Neural Transmission. 2025;132(11):1751-1760. doi:10.1007/s00702-025-03042-7
BibTeX
@article{Yegla2025,
author = {Yegla, Brittney and Rubin, Jonathan and Grall, Mindy and Formella, Andrea and Jenner, Peter},
title = {Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors},
journal = {Journal of Neural Transmission},
year = {2025},
volume = {132},
number = {11},
pages = {1751--1760},
doi = {10.1007/s00702-025-03042-7}
}
EUVIMED